What is Yupelri and What Does it Treat?
Yupelri (revefenacin) is a medication used to treat chronic obstructive pulmonary disease (COPD) [1]. It is an anticholinergic bronchodilator that works by relaxing the muscles around the airways in the lungs, making it easier to breathe [2].
How Can I Save Money on Yupelri?
For individuals seeking to reduce the cost of Yupelri, several options may be available. These include patient assistance programs, savings cards, and potentially generic alternatives if they become available [1][3].
Are There Patient Assistance Programs for Yupelri?
Patient assistance programs are designed to help eligible individuals access necessary medications at a lower cost or for free. Information regarding specific programs for Yupelri can typically be found through the drug's manufacturer or by consulting with a healthcare provider or pharmacist [1][3].
When Will a Generic Version of Yupelri Be Available?
The availability of a generic version of a medication depends on patent expirations and regulatory approvals. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide insights into potential timelines for generic entry [4]. Without specific details on Yupelri's patent landscape, a precise generic availability date cannot be determined.
What Are the Potential Side Effects of Yupelri?
Common side effects associated with Yupelri include dry mouth, urinary tract infections, and constipation [2]. Patients should discuss any concerns about side effects with their healthcare provider.
How Does Yupelri Compare to Other COPD Treatments?
Yupelri is an anticholinergic bronchodilator, a class of medications used for COPD management. Other treatment options for COPD may include different classes of bronchodilators (such as long-acting beta-agonists), inhaled corticosteroids, or combination therapies. The choice of treatment depends on the individual's symptom severity and medical history [2].
Who Manufactures Yupelri?
Yupelri is manufactured by Theravance Biopharma and licensed to Mylan N.V. (now part of Viatris) for commercialization in the United States [1].
---
Sources:
1. Yupelri (revefenacin) Prescribing Information.
2. Mylan N.V. Press Release. (Specific date and title not provided in input).
3. Patient Assistance Program information may vary and is best obtained through direct inquiry with the manufacturer or a healthcare provider.
4. DrugPatentWatch.com.